You have been chosen to receive this valuable information.
 
A SPECIAL
ANNOUNCEMENT FROM:
   PE Logo  
Last week, the Trump administration unveiled a new proposal that aims to reduce reimbursement for medicines administered to seniors under the Medicare Part B benefit to an amount pegged to the average price paid in foreign industrial nations. It would link U.S. prices to an International Pricing Index (IPI) based on sixteen other countries.
It’s a move that could entirely reshape the way pharma and biotech think about their business model in the U.S.
We sat down with Archbow Consulting’s international pricing expert to better understand each brand's risk under the IPI. Read the article for more information on:
• How the proposed IPI compares to International Reference Pricing (IRP)
• Illustrative case studies on the proposed methodology
• If price erosion in countries around the world could impact your brand’s price
• How you can prepare today for the downstream impact of the IPI
Archbow Consulting, 4700 Millenia Blvd.
Suite 175, Orlando, FL 32839
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Pharmaceutical Executive, a UBM publication. You are on the mailing list as %%emailaddress%%.